REFERENCES
-
1
Favaloro E J.
Editorial. Welcome to a special issue of Seminars in Thrombosis and Hemostasis—the closing issue for 2008.
Semin Thromb Hemost.
2008;
34
693-696
-
2
Favaloro E J.
A tribute to Eberhard F. Mammen, M.D. (1930–2008).
Semin Thromb Hemost.
2008;
34
(8)
703-707
-
3
Favaloro E J.
Editorial. Welcome to the first issue of Seminars in Thrombosis and Hemostasis for 2009.
Semin Thromb Hemost.
2009;
35
1-2
-
4
Favaloro E J.
Editorial. Winners of the Inaugural Eberhard F. Mammen Award for Most Popular Article.
Semin Thromb Hemost.
2009;
35
587-590
-
5
Favaloro E J.
Editorial. 2009 Eberhard F. Mammen Young Investigator Award Winners.
Semin Thromb Hemost.
2010;
36
469-470
-
6
Favaloro E J.
Winners of the 2010 Eberhard F. Mammen award for most popular article during 2008–2009.
Semin Thromb Hemost.
2010;
36
(7)
685-692
-
7
Sobieraj-Teague M, O'Donnell M, Eikelboom J.
New anticoagulants for atrial fibrillation.
Semin Thromb Hemost.
2009;
35
(5)
515-524
-
8
Favaloro E J, McDonald D, Lippi G.
Laboratory investigation of thrombophilia: the good, the bad, and the ugly.
Semin Thromb Hemost.
2009;
35
(7)
695-710
-
9
Mariani G, Bernardi F.
Factor VII deficiency.
Semin Thromb Hemost.
2009;
35
(4)
400-406
-
10
Jurk K, Kehrel B E.
Platelets: physiology and biochemistry.
Semin Thromb Hemost.
2005;
31
(4)
381-392
-
11
Viiala N O, Larsen S R, Rasko J E.
Gene therapy for hemophilia: clinical trials and technical tribulations.
Semin Thromb Hemost.
2009;
35
(1)
81-92
-
12
Asherson R A, Cervera R, Merrill J T, Erkan D.
Antiphospholipid antibodies and the antiphospholipid syndrome: clinical significance and treatment.
Semin Thromb Hemost.
2008;
34
(3)
256-266
-
13
Tripodi A, van den Besselaar A.
Laboratory monitoring of anticoagulation: where do we stand?.
Semin Thromb Hemost.
2009;
35
(1)
34-41
-
14
Zhou Z, Nguyen T C, Guchhait P, Dong J F.
von Willebrand factor, ADAMTS-13, and thrombotic thrombocytopenic purpura.
Semin Thromb Hemost.
2010;
36
(1)
71-81
-
15
Lippi G, Franchini M, Favaloro E J, Targher G.
Moderate red wine consumption and cardiovascular disease risk: beyond the “French paradox.”
Semin Thromb Hemost.
2010;
36
(1)
59-70
-
16
Lippi G, Favaloro E J, Franchini M, Guidi G C.
Milestones and perspectives in coagulation and hemostasis.
Semin Thromb Hemost.
2009;
35
(1)
9-22
-
17
Tincani A, Bazzani C, Zingarelli S, Lojacono A.
Lupus and the antiphospholipid syndrome in pregnancy and obstetrics: clinical characteristics, diagnosis, pathogenesis, and treatment.
Semin Thromb Hemost.
2008;
34
(3)
267-273
-
18
Karimi M, Bereczky Z, Cohan N, Muszbek L.
Factor XIII deficiency.
Semin Thromb Hemost.
2009;
35
(4)
426-438
-
19
Harenberg J, Wehling M.
Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa.
Semin Thromb Hemost.
2008;
34
(1)
39-57
-
20
Althaus K, Greinacher A.
MYH9-related platelet disorders.
Semin Thromb Hemost.
2009;
35
(2)
189-203
-
21
Fareed J, Hoppensteadt D A, Fareed D et al..
Survival of heparins, oral anticoagulants, and aspirin after the year 2010.
Semin Thromb Hemost.
2008;
34
(1)
58-73
-
22
Wada H, Usui M, Sakuragawa N.
Hemostatic abnormalities and liver diseases.
Semin Thromb Hemost.
2008;
34
(8)
772-778
-
23
Pierangeli S S, Chen P P, Raschi E et al..
Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms.
Semin Thromb Hemost.
2008;
34
(3)
236-250
-
24
McGlasson D L, Fritsma G A.
Whole blood platelet aggregometry and platelet function testing.
Semin Thromb Hemost.
2009;
35
(2)
168-180
-
25
de Moerloose P, Neerman-Arbez M.
Congenital fibrinogen disorders.
Semin Thromb Hemost.
2009;
35
(4)
356-366
-
26
Favaloro E J.
Clinical utility of the PFA-100.
Semin Thromb Hemost.
2008;
34
(8)
709-733
-
27
Wong R C, Favaloro E J.
Clinical features, diagnosis, and management of the antiphospholipid syndrome.
Semin Thromb Hemost.
2008;
34
(3)
295-304
-
28
Brenner B, Kuperman A A, Watzka M, Oldenburg J.
Vitamin K–dependent coagulation factors deficiency.
Semin Thromb Hemost.
2009;
35
(4)
439-446
-
29
Gisondi P, Girolomoni G.
Psoriasis and atherothrombotic diseases: disease-specific and non-disease-specific risk factors.
Semin Thromb Hemost.
2009;
35
(3)
313-324
-
30
Asselta R, Peyvandi F.
Factor V deficiency.
Semin Thromb Hemost.
2009;
35
(4)
382-389
-
31
Blum W, Porcu P.
Therapeutic apheresis in hyperleukocytosis and hyperviscosity syndrome.
Semin Thromb Hemost.
2007;
33
(4)
350-354
-
32
Blann A, Shantsila E, Shantsila A.
Microparticles and arterial disease.
Semin Thromb Hemost.
2009;
35
(5)
488-496
-
33
Hunt B J.
Pediatric antiphospholipid antibodies and antiphospholipid syndrome.
Semin Thromb Hemost.
2008;
34
(3)
274-281
-
34
Harrison P, Mumford A.
Screening tests of platelet function: update on their appropriate uses for diagnostic testing.
Semin Thromb Hemost.
2009;
35
(2)
150-157
-
35
Galli M.
Clinical utility of laboratory tests used to identify antiphospholipid antibodies and to diagnose the antiphospholipid syndrome.
Semin Thromb Hemost.
2008;
34
(4)
329-334
-
36
Menegatti M, Peyvandi F.
Factor X deficiency.
Semin Thromb Hemost.
2009;
35
(4)
407-415
-
37
Enjeti A K, Lincz L F, Seldon M.
Detection and measurement of microparticles: an evolving research tool for vascular biology.
Semin Thromb Hemost.
2007;
33
(8)
771-779
-
38
Harenberg J.
New anticoagulants in atrial fibrillation.
Semin Thromb Hemost.
2009;
35
(6)
574-585
-
39
Duga S, Salomon O.
Factor XI deficiency.
Semin Thromb Hemost.
2009;
35
(4)
416-425
y
-
40
Harenberg J.
Development of new anticoagulants: present and future.
Semin Thromb Hemost.
2008;
34
(8)
779-793
-
41
Hellgren M.
Hemostasis during normal pregnancy and puerperium.
Semin Thromb Hemost.
2003;
29
(2)
125-130
-
42
Levi M, Löwenberg E C.
Thrombocytopenia in critically ill patients.
Semin Thromb Hemost.
2008;
34
(5)
417-424
-
43
Meltzer M E, Doggen C J, de Groot P G, Rosendaal F R, Lisman T.
The impact of the fibrinolytic system on the risk of venous and arterial thrombosis.
Semin Thromb Hemost.
2009;
35
(5)
468-477
-
44
Peyvandi F, Palla R, Menegatti M, Mannucci P M.
Introduction. Rare bleeding disorders: general aspects of clinical features, diagnosis, and management.
Semin Thromb Hemost.
2009;
35
(4)
349-355
-
45
Zuern C S, Lindemann S, Gawaz M.
Platelet function and response to aspirin: gender-specific features and implications for female thrombotic risk and management.
Semin Thromb Hemost.
2009;
35
(3)
295-306
-
46
Berntorp E, Salvagno G L.
Standardization and clinical utility of thrombin-generation assays.
Semin Thromb Hemost.
2008;
34
(7)
670-682
-
47
Baskurt O K, Meiselman H J.
Blood rheology and hemodynamics.
Semin Thromb Hemost.
2003;
29
(5)
435-450
-
48
Roberts H R, Hoffman M, Monroe D M.
A cell-based model of thrombin generation.
Semin Thromb Hemost.
2006;
32
(Suppl 1)
32-38
-
49
Bernardi E, Pesavento R, Prandoni P.
Upper extremity deep venous thrombosis.
Semin Thromb Hemost.
2006;
32
(7)
729-736
-
50
Prisco D, Grifoni E.
The role of D-dimer testing in patients with suspected venous thromboembolism.
Semin Thromb Hemost.
2009;
35
(1)
50-59
-
51
Prechel M, Walenga J M.
The laboratory diagnosis and clinical management of patients with heparin-induced thrombocytopenia: an update.
Semin Thromb Hemost.
2008;
34
(1)
86-96
-
52
Kamphuisen P W, Rosendaal F R, Büller H R.
Hemostatic abnormalities and arterial thrombosis.
Semin Thromb Hemost.
2009;
35
(5)
449-450
-
53
Levi M, Schouten M, van der Poll T.
Sepsis, coagulation, and antithrombin: old lessons and new insights.
Semin Thromb Hemost.
2008;
34
(8)
742-746
-
54
Coppola A, Tufano A, Cerbone A M, Di Minno G.
Inherited thrombophilia: implications for prevention and treatment of venous thromboembolism.
Semin Thromb Hemost.
2009;
35
(7)
683-694
-
55
Selleng K, Selleng S, Greinacher A.
Heparin-induced thrombocytopenia in intensive care patients.
Semin Thromb Hemost.
2008;
34
(5)
425-438
-
56
Mezzano D, Quiroga T, Pereira J.
The level of laboratory testing required for diagnosis or exclusion of a platelet function disorder using platelet aggregation and secretion assays.
Semin Thromb Hemost.
2009;
35
(2)
242-254
-
57
Hayward C P, Favaloro E J.
Diagnostic evaluation of platelet disorders: the past, the present, and the future.
Semin Thromb Hemost.
2009;
35
(2)
127-130
-
58
Peyvandi F, Favaloro E J.
Rare bleeding disorders.
Semin Thromb Hemost.
2009;
35
(4)
345-347
-
59
Wong R C, Favaloro E J.
Antiphospholipid antibodies and the antiphospholipid syndrome. I: pathogenesis, clinical features, diagnosis, and management. Preface.
Semin Thromb Hemost.
2008;
34
(3)
213-218
-
60
Lippi G, Favaloro E J, Franchini M.
Laboratory diagnostics and therapy in thrombosis and hemostasis: from bedside to bench to bedside.
Semin Thromb Hemost.
2009;
35
(1)
3-8
-
61
Franchini M, Lippi G, Favaloro E J.
Coagulopathies and thrombosis: usual and unusual causes and associations, part I.
Semin Thromb Hemost.
2009;
35
(3)
257-259
-
62
Kamphuisen P W, Rosendaal F R, Büller H R.
Hemostatic abnormalities and arterial thrombosis.
Semin Thromb Hemost.
2009;
35
(5)
449-450
-
63
Levi M.
Hemostasis and thrombosis in critically ill patients.
Semin Thromb Hemost.
2008;
34
(5)
415-416
-
64
Favaloro E J.
Hot topics II: an editorial collection of current issues and controversies in thrombosis and hemostasis.
Semin Thromb Hemost.
2008;
34
(1)
3-6
-
65
Favaloro E J.
A tribute to Eberhard F. Mammen, M.D. (1930–2008).
Semin Thromb Hemost.
2008;
34
(8)
703-707
Emmanuel J FavaloroPh.D. F.F.Sc. (RCPA)
Department of Haematology, Institute of Clinical Pathology and Medical Research (ICPMR), Westmead Hospital
SWAHS, Westmead, NSW, 2145, Australia
eMail: emmanuel.favaloro@swahs.health.nsw.gov.au
